Founded in 2019, BigHat Biosciences’ mission is to improve human health by reimagining antibody discovery and engineering to create better antibodies faster. Their integrated computational + experimental approach speeds up antibody design and discovery by combining high-speed molecular characterization with machine learning technologies to guide the search for better antibodies.
BigHat uses continuous integration and continuous deployment (CI/CD) throughout their data engineering workflows and when training and evaluating their machine learning (ML) models.
In the case of BigHat, they apply CI/CD in their data engineering workflows and in training their ML models.
They face risk in finding the right problem, in finding a solution to that problem, and in finding a viable customer base to buy that solution.